🚨🇺🇸 THE U.S. JUST CAPPED OZEMPIC-STYLE DRUGS AT $50 A MONTH - AND IT CHANGES EVERYTHING The U.S. government is moving to cap weight-loss drugs like Wegovy and Zepbound at $50 per month for people on Medicare. These are the same drugs that currently cost close to $1,000 a month if you pay out of pocket. This happened because the Trump administration negotiated steep price cuts with Novo Nordisk and Eli Lilly, then Medicare and Medicaid built a new coverage model on top of that deal. The program is voluntary, but the price is real. Medicaid patients could see access as early as May 2026. Medicare follows in January 2027, with a temporary rollout starting July 2026 so patients don’t have to wait. The government isn’t doing this out of kindness. It’s doing it because obesity is one of the biggest cost drivers in the entire healthcare system. Heart attacks, diabetes complications, joint replacements, and long-term disability cost far more than paying for the drug that prevents them. This is a budget decision, not a cultural one. What makes this matter is scale. Medicare is the largest drug buyer in the world. When it sets a price, private insurers eventually fall in line. Employers won’t keep paying ten times more than the federal government. And once oral weight-loss pills hit the market, prices will compress even further. The result is simple: these drugs stop being luxury medicine. Coverage expands. Stigma fades. Treatment becomes routine. America sidelined discipline. It discovered bulk pricing. Source: Reuters, CBS News